kynurenic acid has been researched along with Cognition Disorders in 9 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aim & Objective: To delineate the associations between executive impairments and changes in tryptophan catabolite (TRYCAT) patterning, negative symptoms and deficit schizophrenia." | 7.88 | The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling. ( Kanchanatawan, B; Maes, M, 2018) |
| "Elevated cerebrospinal fluid (CSF) levels of the glia-derived N-methyl-D-aspartic acid receptor antagonist kynurenic acid (KYNA) have consistently been implicated in schizophrenia and bipolar disorder." | 7.83 | A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. ( Backlund, L; Bergen, SE; Ekman, CJ; Engberg, G; Erhardt, S; Hultman, CM; Kegel, ME; Landén, M; Larsson, M; Lichtenstein, P; Magnusson, PK; Olsson, S; Schalling, M; Sellgren, CM; Sklar, P; Smoller, JW; Sullivan, PF; Svensson, CI; Vawter, MP; Walther-Jallow, L, 2016) |
| "Aim & Objective: To delineate the associations between executive impairments and changes in tryptophan catabolite (TRYCAT) patterning, negative symptoms and deficit schizophrenia." | 3.88 | The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling. ( Kanchanatawan, B; Maes, M, 2018) |
| "Elevated cerebrospinal fluid (CSF) levels of the glia-derived N-methyl-D-aspartic acid receptor antagonist kynurenic acid (KYNA) have consistently been implicated in schizophrenia and bipolar disorder." | 3.83 | A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. ( Backlund, L; Bergen, SE; Ekman, CJ; Engberg, G; Erhardt, S; Hultman, CM; Kegel, ME; Landén, M; Larsson, M; Lichtenstein, P; Magnusson, PK; Olsson, S; Schalling, M; Sellgren, CM; Sklar, P; Smoller, JW; Sullivan, PF; Svensson, CI; Vawter, MP; Walther-Jallow, L, 2016) |
| "Only kynurenine-treated rats were impaired in acquiring the extra-dimensional shift (saline, 8." | 1.38 | Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. ( Alexander, KS; Bruno, JP; Schwarcz, R; Wu, HQ, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanchanatawan, B | 1 |
| Maes, M | 1 |
| Pocivavsek, A | 2 |
| Thomas, MA | 1 |
| Elmer, GI | 2 |
| Bruno, JP | 3 |
| Schwarcz, R | 3 |
| Sellgren, CM | 1 |
| Kegel, ME | 1 |
| Bergen, SE | 1 |
| Ekman, CJ | 1 |
| Olsson, S | 1 |
| Larsson, M | 1 |
| Vawter, MP | 1 |
| Backlund, L | 1 |
| Sullivan, PF | 1 |
| Sklar, P | 1 |
| Smoller, JW | 1 |
| Magnusson, PK | 1 |
| Hultman, CM | 1 |
| Walther-Jallow, L | 1 |
| Svensson, CI | 1 |
| Lichtenstein, P | 1 |
| Schalling, M | 1 |
| Engberg, G | 2 |
| Erhardt, S | 2 |
| Landén, M | 1 |
| Olsson, SK | 1 |
| Alexander, KS | 1 |
| Wu, HQ | 2 |
| Szalardy, L | 1 |
| Zadori, D | 1 |
| Toldi, J | 1 |
| Fulop, F | 1 |
| Klivenyi, P | 1 |
| Vecsei, L | 1 |
| Schwarz, MJ | 1 |
| Guillemin, GJ | 1 |
| Teipel, SJ | 1 |
| Buerger, K | 1 |
| Hampel, H | 1 |
| Ramakers, GM | 1 |
| Urban, IJ | 1 |
| De Graan, PN | 1 |
| Di Luca, M | 1 |
| Cattabeni, F | 1 |
| Gispen, WH | 1 |
2 reviews available for kynurenic acid and Cognition Disorders
| Article | Year |
|---|---|
Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.
Topics: Animals; Cognition Disorders; Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Kynurenine; | 2009 |
Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction.
Topics: Binding Sites; Brain; Cognition Disorders; Glycine; Humans; Kynurenic Acid | 2012 |
7 other studies available for kynurenic acid and Cognition Disorders
| Article | Year |
|---|---|
The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Cognition Disorders; Executive Function; Female; Huma | 2018 |
Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats.
Topics: Age Factors; Animals; Avoidance Learning; Behavior, Animal; Cognition Disorders; Female; Hippocampus | 2014 |
A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder.
Topics: Adult; Aged; Bipolar Disorder; Brain; Chromosomes, Human, Pair 1; Cognition Disorders; Cognitive Dys | 2016 |
Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Cognition; Cognition Disorders; Disease Mod | 2012 |
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Chromatography, High Pressure Liquid; | 2012 |
Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.
Topics: Aged; Alzheimer Disease; Biomarkers; Blood-Brain Barrier; Brain Chemistry; Chromatography, High Pres | 2013 |
The impaired long-term potentiation in the CA1 field of the hippocampus of cognitive deficient microencephalic rats is restored by D-serine.
Topics: 2-Amino-5-phosphonovalerate; Animals; Brain; Cognition Disorders; Electric Stimulation; Electrophysi | 1993 |